clinical trial · NCT04940390
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Satsuma Pharmaceuticals, Inc.·phase3·completed·n = 1,591
MigraineMigraine With AuraMigraine Without AuraDihydroergotaminePlacebo
brief summary
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
started
Jun 30, 2021
primary completion
Oct 13, 2022
completion
Oct 26, 2022
last updated
Nov 27, 2023
detailed description
Study STS101-007 is a multi-center, single-dose, randomized, double-blind, placebo-controlled, parallel group study in subjects with acute migraine (ages 18 to 65 years).
official title
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol